Phase I/II Study of Continuous-Infusion Troxacitabine in Refractory Acute Myeloid Leukemia

• Published in: Journal of clinical oncology Vol. 25; no. 1; pp. 10 - 15
• Main Authors: ROBOZ, Gail, GILES, Francis J, KELNER, Michael J, FELDMAN, Eric J, RITCHIE, Ellen K, ALLEN-BARD, Sandra, CURCIO, Tania J, WILKES, Meredith A, LANI PARK, S, KANTARJIAN, Hagop M, FADERL, Stefan, RAVANDI, Farhad
• Format: Journal Article
• Language: English
• Published: Baltimore, MD American Society of Clinical Oncology 01.01.2007; Lippincott Williams & Wilkins
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Biological and medical sciences; Cytosine - administration & dosage; Cytosine - analogs & derivatives; Cytosine - pharmacokinetics; Dioxolanes - administration & dosage; Dioxolanes - pharmacokinetics; Female; Hematologic and hematopoietic diseases; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute - drug therapy; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Time Factors; Treatment Outcome; Tumors; Antineoplastic agent; Treatment resistance; Cancerology; Treatment; Troxacitabine; Perfusion; Phase II trial; Phase I trial; Nucleoside analog; Malignant hemopathy; Acute myelocytic leukemia

Troxacitabine is a non-natural nucleoside analog with unique structural and metabolic features. Bolus intravenous (IV) troxacitabine regimens have shown significant activity in patients with refractory acute myeloid leukemia (AML) and preclinical data suggest that administration via continuous infus...